Wegovy opinions: what real decisions look like when the hype settles

The results picture: what the evidence shows and where opinions split

The most persistent misconception about Wegovy is that "it just works automatically, without any effort". Prescribers hear this regularly, and it's worth letting go of gently: the trial data make clear that participants followed a reduced-calorie diet and increased activity alongside treatment. STEP 1, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity and found roughly 15% average weight loss over 68 weeks. That's a clinically significant figure. But "average" is doing a lot of work in that sentence, some participants lost considerably more, others less, and a small number found the medicine didn't suit them at all.

Opinions about effectiveness divide roughly along these lines: people who respond well and tolerate the side-effect profile tend to be positive; people who experience persistent nausea or who expected faster results tend to be more ambivalent. Neither camp is wrong. The medicine works through a GLP-1 receptor pathway that reduces appetite and slows gastric emptying, and the physiological response does differ between individuals. What one person describes as a near-effortless reduction in hunger, another finds modest against the side effects they have to manage.

The newer 7.2mg dose, approved by the MHRA in April 2026, has generated renewed interest precisely because average weight loss in trials at that level approached 20.7%, which changes the picture for people who felt 15% wasn't enough to pursue treatment. It's licensed for adults with a BMI of at least 30. Whether the higher dose is clinically appropriate for a given person is a decision made by the prescribing clinician.

Side effects: the reason most mixed opinions exist

Almost every nuanced opinion about Wegovy circles back to the side-effect experience in the first few months. Nausea is the most frequently reported complaint, followed by diarrhoea, constipation, reflux and fatigue. These are consistent with the GLP-1 mechanism, the medicine slows how quickly food leaves the stomach, and the gut takes time to adjust.

The titration schedule exists for exactly this reason. Treatment starts at 0.25mg and increases gradually, typically every four weeks, up to the 2.4mg maintenance dose. People who rush the process tend to report worse nausea; people who stay patient often find the side effects are most noticeable in the first couple of dose increases and then settle. That pattern appears in the clinical data and matches what prescribers observe. It doesn't make the early weeks comfortable, but it does make them predictable.

If you're weighing opinions and wondering whether you'd tolerate it: nausea on starting or increasing a dose is common and typically peaks within the first few days before easing. Persistent vomiting, severe abdominal pain that spreads to the back, or symptoms that prevent you from keeping fluids down are different, those need prompt medical attention. Anyone on Wegovy can report unexpected symptoms to the MHRA Yellow Card scheme. Knowing that is practical, not alarming.

Practicalities that shape long-term opinions

Beyond results and side effects, opinion divides on the practical experience of being on weekly injections long-term. Storage in the fridge, rotating injection sites, managing the pen while travelling, these are small things that accumulate. For most people they become routine within a few weeks. Others find the weekly commitment harder than expected, particularly if doses are missed and they're unsure how to proceed (the PIL and prescriber are the right guides there, not forums).

Cost also shapes how people feel about the treatment over time. Private treatment is priced per month and the full picture (consultation, prescription, clinical re-review at each repeat order, delivery and aftercare access) matters as much as the headline figure. You can explore what's involved in how Wegovy is priced privately, or look at the semaglutide options available if you're deciding between formulations. For anyone curious about how semaglutide compares across formats, our semaglutide overview covers the landscape clearly.

Surgery deserves a mention here because it comes up in opinions forums often: if you're having or planning an operation, your healthcare team including the anaesthetist needs to know you're taking a GLP-1 medicine. More on that is covered on the Wegovy and operations page.

Making the decision: what a consultation is actually for

The decision to start Wegovy isn't one you can fully make from reading other people's experiences. Eligibility under the UK licence covers adults with a BMI of at least 30, or at least 27 with a weight-related condition such as hypertension or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. But eligibility in principle and suitability in your specific situation are different things, your medical history, current medicines and weight-management goals all feed into that clinical assessment.

A prescriber isn't just a gatekeeper for the medicine. They're also the right person to discuss which formulation suits you (including whether the full Wegovy range or a different approach fits better), how to handle the early weeks, and what to monitor. If you want to explore what getting started looks like, the common questions about Wegovy page covers the logistics. And if you'd like to understand the broader weight-loss treatment options before narrowing down, that's a reasonable starting point too.

Our prescribers review every consultation personally, the same day, on working days. There's no algorithm deciding your suitability; a real clinician reads your answers. Speak to our prescribers through a free consultation if you'd like a clinical view on whether Wegovy is right for you.